These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 24609871)

  • 1. DCE-MRI biomarkers for monitoring an anti-angiogenic triple combination therapy in experimental hypopharynx carcinoma xenografts with immunohistochemical validation.
    Sterzik A; Paprottka PM; Zengel P; Hirner H; Roßpunt S; Eschbach R; Moser M; Havla L; Ingrisch M; Mack B; Reiser MF; Nikolaou K; Cyran CC
    Acta Radiol; 2015 Mar; 56(3):294-303. PubMed ID: 24609871
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reducing tumor growth and angiogenesis using a triple therapy measured with Contrast-enhanced ultrasound (CEUS).
    Paprottka PM; Roßpunt S; Ingrisch M; Cyran CC; Nikolaou K; Reiser MF; Mack B; Gires O; Clevert DA; Zengel P
    BMC Cancer; 2015 May; 15():373. PubMed ID: 25947947
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dynamic contrast-enhanced computed tomography imaging biomarkers correlated with immunohistochemistry for monitoring the effects of sorafenib on experimental prostate carcinomas.
    Cyran CC; von Einem JC; Paprottka PM; Schwarz B; Ingrisch M; Dietrich O; Hinkel R; Bruns CJ; Clevert DA; Eschbach R; Reiser MF; Wintersperger BJ; Nikolaou K
    Invest Radiol; 2012 Jan; 47(1):49-57. PubMed ID: 21934514
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vivo monitoring of sorafenib therapy effects on experimental prostate carcinomas using dynamic contrast-enhanced MRI and macromolecular contrast media.
    Cyran CC; Schwarz B; Paprottka PM; Sourbron S; von Einem JC; Dietrich O; Hinkel R; Clevert DA; Bruns CJ; Reiser MF; Nikolaou K; Wintersperger BJ
    Cancer Imaging; 2013 Dec; 13(4):557-66. PubMed ID: 24380871
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Measurement of tumor blood flow in head and neck squamous cell carcinoma by pseudo-continuous arterial spin labeling: comparison with dynamic contrast-enhanced MRI.
    Fujima N; Kudo K; Tsukahara A; Yoshida D; Sakashita T; Homma A; Tha KK; Shirato H
    J Magn Reson Imaging; 2015 Apr; 41(4):983-91. PubMed ID: 25787123
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Contrast-Enhanced Ultrasound with VEGFR2-Targeted Microbubbles for Monitoring Regorafenib Therapy Effects in Experimental Colorectal Adenocarcinomas in Rats with DCE-MRI and Immunohistochemical Validation.
    Eschbach RS; Clevert DA; Hirner-Eppeneder H; Ingrisch M; Moser M; Schuster J; Tadros D; Schneider M; Kazmierczak PM; Reiser M; Cyran CC
    PLoS One; 2017; 12(1):e0169323. PubMed ID: 28060884
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intravoxel incoherent motion diffusion-weighted imaging in head and neck squamous cell carcinoma: assessment of perfusion-related parameters compared to dynamic contrast-enhanced MRI.
    Fujima N; Yoshida D; Sakashita T; Homma A; Tsukahara A; Tha KK; Kudo K; Shirato H
    Magn Reson Imaging; 2014 Dec; 32(10):1206-13. PubMed ID: 25131628
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Early antiangiogenic activity of SU11248 evaluated in vivo by dynamic contrast-enhanced magnetic resonance imaging in an experimental model of colon carcinoma.
    Marzola P; Degrassi A; Calderan L; Farace P; Nicolato E; Crescimanno C; Sandri M; Giusti A; Pesenti E; Terron A; Sbarbati A; Osculati F
    Clin Cancer Res; 2005 Aug; 11(16):5827-32. PubMed ID: 16115922
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Perfusion MRI for monitoring the effect of sorafenib on experimental prostate carcinoma: a validation study.
    Cyran CC; Paprottka PM; Schwarz B; Sourbron S; Ingrisch M; von Einem J; Pietsch H; Dietrich O; Hinkel R; Bruns CJ; Reiser MF; Wintersperger BJ; Nikolaou K
    AJR Am J Roentgenol; 2012 Feb; 198(2):384-91. PubMed ID: 22268182
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Correlation of perfusion MRI and 18F-FDG PET imaging biomarkers for monitoring regorafenib therapy in experimental colon carcinomas with immunohistochemical validation.
    Eschbach RS; Fendler WP; Kazmierczak PM; Hacker M; Rominger A; Carlsen J; Hirner-Eppeneder H; Schuster J; Moser M; Havla L; Schneider MJ; Ingrisch M; Spaeth L; Reiser MF; Nikolaou K; Cyran CC
    PLoS One; 2015; 10(2):e0115543. PubMed ID: 25668193
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Measurement of tumor blood flow in head and neck squamous cell carcinoma by pseudo-continuous arterial spin labeling: comparison with dynamic contrast-enhanced MRI.
    Fujima N; Kudo K; Tsukahara A; Yoshida D; Sakashita T; Homma A; Tha KK; Shirato H
    J Magn Reson Imaging; 2015 Apr; 41(4):983-91. PubMed ID: 24723251
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dynamic contrast-enhanced micro-computed tomography correlates with 3-dimensional fluorescence ultramicroscopy in antiangiogenic therapy of breast cancer xenografts.
    Pöschinger T; Renner A; Eisa F; Dobosz M; Strobel S; Weber TG; Brauweiler R; Kalender WA; Scheuer W
    Invest Radiol; 2014 Jul; 49(7):445-56. PubMed ID: 24598441
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MR monitoring of cyclooxygenase-2 inhibition of angiogenesis in a human breast cancer model in rats.
    Fournier LS; Novikov V; Lucidi V; Fu Y; Miller T; Floyd E; Shames DM; Brasch RC
    Radiology; 2007 Apr; 243(1):105-11. PubMed ID: 17329684
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The temporal correlation of dynamic contrast-enhanced magnetic resonance imaging with tumor angiogenesis in a murine glioblastoma model.
    Veeravagu A; Hou LC; Hsu AR; Cai W; Greve JM; Chen X; Tse V
    Neurol Res; 2008 Nov; 30(9):952-9. PubMed ID: 18662497
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dynamic contrast-enhanced magnetic resonance imaging rapidly indicates vessel regression in human squamous cell carcinomas grown in nude mice caused by VEGF receptor 2 blockade with DC101.
    Kiessling F; Farhan N; Lichy MP; Vosseler S; Heilmann M; Krix M; Bohlen P; Miller DW; Mueller MM; Semmler W; Fusenig NE; Delorme S
    Neoplasia; 2004; 6(3):213-23. PubMed ID: 15153333
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of a novel macromolecular cascade-polymer contrast medium for dynamic contrast-enhanced MRI monitoring of antiangiogenic bevacizumab therapy in a human melanoma model.
    Cyran CC; Fu Y; Rogut V; Chaopathomkul B; Wendland MF; Shames DM; Brasch RC
    Acad Radiol; 2013 Oct; 20(10):1256-63. PubMed ID: 24029057
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combining dynamic contrast enhanced magnetic resonance imaging and microvessel density to assess the angiogenesis after PEI in a rabbit VX2 liver tumor model.
    Chen J; Qian T; Zhang H; Wei C; Meng F; Yin H
    Magn Reson Imaging; 2016 Feb; 34(2):177-82. PubMed ID: 26518059
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bevacizumab enhances the therapeutic efficacy of Irinotecan against human head and neck squamous cell carcinoma xenografts.
    Cao S; Durrani FA; Toth K; Rustum YM; Seshadri M
    Oral Oncol; 2011 Jun; 47(6):459-66. PubMed ID: 21530364
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-angiogenic Effects of Bumetanide Revealed by DCE-MRI with a Biodegradable Macromolecular Contrast Agent in a Colon Cancer Model.
    Malamas AS; Jin E; Zhang Q; Haaga J; Lu ZR
    Pharm Res; 2015 Sep; 32(9):3029-43. PubMed ID: 25840948
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dynamic contrast-enhanced magnetic resonance imaging for monitoring the anti-angiogenesis efficacy in a C6 glioma rat model.
    Hou W; Li X; Pan H; Xu M; Bi S; Shen Y; Yu Y
    Acta Radiol; 2020 Jul; 61(7):973-982. PubMed ID: 31739674
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.